3月3日 - ** 制药商TG Therapeutics TGTX.O股价上涨15.7%至34.82美元
** (link) 公司第四季度 产品净收入为 1.073 亿美元，超过分析师平均预期的 9998 万美元--数据由 LSEG 编制
** TGTX公司第四季度复发性多发性硬化症药物Briumvi在 美国的产品净营收为 1.036亿美元。
** 公司预测 2025 年总收入约为 5.4亿美元， 预计为5.482 亿美元
** TGTX 在过去 12 个月中上涨了 71
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.